← All opportunities

TÜBİTAK · Turkey

EP PerMed 2027 — Cell and Gene Therapies for Personalised Medicine (Turkey participation)

Open

Applications close on 20 Jan 2027.

Note: international consortium and national application required.

Programme overview

The 2027 joint call supports development and validation of innovative cell and gene therapies for personalised human medicine. Approaches include somatic-cell therapies, gene therapies, combined cell/gene therapies and specified biological products. Proposals are submitted by multinational consortia through a two-stage international process.

Who can apply

Participating Turkish researchers must also submit a national application to TÜBİTAK. The national route uses programme 1071; consortium and national eligibility rules both apply.

Applicant categories are a starting point. The official call decides eligibility.

Timing

International short proposal: 20 January 2027, 14:00 CET. National submissions and later stages have separate deadlines; consult the official call timetable.

How to apply

1. Check consortium composition, scientific scope and national eligibility.
2. Coordinate the international short proposal before 20 January 2027, 14:00 CET.
3. Complete the separate TÜBİTAK national application and any later stages on their own schedules.

From the call text

Who can apply

Not stated in the call text we hold — check the official page

Company stage

Not stated in the call text we hold — check the official page

Single applicant or consortium

The national route uses programme 1071; consortium and national eligibility rules both apply.

Where applicants must be based

Not stated in the call text we hold — check the official page

Where to apply

Not stated in the call text we hold — check the official page

Where these facts come from

Official sources

Official call page

Facts on this page were read from the official page on 11 Nov 2026. The funder's own documents, including later amendments, always take precedence.

More from TÜBİTAK